Format

Send to

Choose Destination
See comment in PubMed Commons below
Adv Drug Deliv Rev. 2005 Dec 14;57(15):2177-202. Epub 2005 Nov 28.

Dendrimers in gene delivery.

Author information

1
Cancer Research UK Centre for Oncology and Applied Pharmacology, Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK.

Abstract

Dendrimers have unique molecular architectures and properties that make them attractive materials for the development of nanomedicines. Key properties such as defined architecture and a high ratio of multivalent surface moieties to molecular volume also make these nanoscaled materials highly interesting for the development of synthetic (non-viral) vectors for therapeutic nucleic acids. Rational development of such vectors requires the link to be made between dendrimer structure and the morphology and physicochemistry of the respective nucleic acid complexes and, furthermore, to the biological performance of these systems at the cellular and systemic level. The review focuses on the current understanding of the role of dendrimers in those aspects of synthetic vector development. Dendrimer-based transfection agents have become routine tools for many molecular and cell biologists but therapeutic delivery of nucleic acids remains a challenge.

PMID:
16310284
DOI:
10.1016/j.addr.2005.09.017
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center